Fund Close
5 November 2026NSV secures nearly $55 million at first close of its debut biotech fund
Nearly $55 million
Venture capital firm NSV has reached a first close of nearly $55 million for its first biotechnology fund. This is an initial close rather than a reported final close.
What it means for founders
Biotech founders have a newly capitalized venture fund to assess as a potential investor.
Biotechnology
Source: WSJ
Summary written by Venturly. Read the original article for full details.